Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease in developed
countries. Its frequency is increasing in the general population mostly due to the widespread …

Potential hepatotoxicity related to amiodarone therapy is often a concern when deciding
whether to initiate or continue treatment with this medication. While mostly associated with …

Drug‐induced liver injury (DILI) encompasses a spectrum of liver diseases from acute and
chronic hepatitis, cholestatic syndromes, and vascular lesions through to benign and …

Drug-induced liver disease in 2006 : Current Opinion in Gastroenterology Drug-induced liver
disease in 2006 : Current Opinion in Gastroenterology Log in or Register Subscribe to …

Nonalcoholic steatosis/steatohepatitis is the most common cause for abnormal liver
chemistries. Apart from metabolic syndrome, drugs may also lead to development of …

Introduction. Amiodarone has been used for more than 5 decades for the treatment of
various tachyarrhythmias and previously for the treatment of refractory angina. There are …

Лекарственно-ассоциированная жировая болезнь печени (ЛЖБП) это группа
осложнений фармакотерапии, распространенность которых составляет около 10% от …

Background: Amiodarone is associated with varying degrees of hepatotoxicity. Aims: to
study the association between the presence of the metabolic syndrome or rightsided heart …

This cross-sectional, retrospective study was designed to evaluate the current clinical
applications and acute hepatotoxicity of intravenous amiodarone administration at a hospital …

Drug-induced fatty liver disease (DIFLD) covers a group of adverse drug reactions whose
prevalence accounts for about 10% of all adverse reactions. The aim of this review was to …